Want to see CALC full AI Analyst Report?
CALC Stock Chart & Stats
$0.60
<$0.01(0.05%)
At close: 4:00 PM EST
$0.60
<$0.01(0.05%)
Day’s Range― - ―
52-Week Range$0.46 - $7.20
Previous CloseN/A
Volume2.29K
Average Volume (3M)71.94K
Market Cap
$21.33M
Enterprise Value$5.11M
Total Cash (Recent Filing)$8.16M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.21
Next Earnings
Aug 18, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.33
Shares Outstanding30,736,400
10 Day Avg. Volume167,963
30 Day Avg. Volume71,939
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-14.90K
Price to Sales (P/S)0.00
P/FCF Ratio-4.66K
Enterprise Value/Market Cap0.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-729.48
Enterprise Value/Ebitda-0.28
Forecast
1Y Price Target
$10.00Price Target Upside1566.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.62
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Safety FeedbackThe FDA's absence of comments on the KOURAGE protocol amendment and safety data materially strengthens Auxora's clinical safety profile. This durable validation reduces regulatory execution risk, supports resumed enrollment and future pivotal discussions, and preserves the program's path toward late-stage development.
Extended Runway Via Private PlacementThe ~$15M raise materially extends operational runway into 2H 2027, enabling planned Phase 1b and IND-enabling work. This reduces near-term financing urgency, allowing management to execute on clinical milestones that can de-risk programs and improve prospects for non-dilutive or partnership funding.
Platform And Indication StrategyCalciMedica's CRAC-channel platform targets multiple high-need inflammatory and cardiopulmonary diseases. A platform approach and parallel development (IV Auxora and oral CM5480) creates multiple value pathways, diversifies program risk and increases long-term upside if one indication yields positive readthroughs.
Bears Say
Pre-revenue Cash BurnAs a pre-revenue biotech generating no product cash flows and burning ~-$21.2M TTM, the company remains dependent on external capital to fund operations and trials. This structural cash consumption necessitates periodic raises, constraining strategic flexibility and making long-term plans contingent on successful financings or partnerships.
Weakened Balance SheetNegative stockholders' equity and a shrinking asset base reduce financial resilience and may impair access to favorable financing or partnerships. Structurally, negative equity signals accumulated losses that can complicate negotiations, limit collateral for lenders, and increase the likelihood of dilutive remedies.
Equity-linked Financings And Dilution RiskDebt amendments and re-priced/added warrants materially increase potential equity dilution and ownership uncertainty. These durable capital-structure changes mean future upside to current holders can be diluted by conversions/exercises, and the company may face higher effective funding costs tied to equity rather than non-dilutive alternatives.
CalciMedica News
CALC FAQ
What was CalciMedica’s price range in the past 12 months?
CalciMedica lowest stock price was $0.46 and its highest was $7.20 in the past 12 months.
What is CalciMedica’s market cap?
CalciMedica’s market cap is $21.33M.
When is CalciMedica’s upcoming earnings report date?
CalciMedica’s upcoming earnings report date is Aug 18, 2026 which is in 30 days.
How were CalciMedica’s earnings last quarter?
CalciMedica released its earnings results on May 12, 2026. The company reported $0.3 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.58.
Is CalciMedica overvalued?
According to Wall Street analysts CalciMedica’s price is currently Undervalued.
Does CalciMedica pay dividends?
CalciMedica does not currently pay dividends.
What is CalciMedica’s EPS estimate?
CalciMedica’s EPS estimate is -0.29.
How many shares outstanding does CalciMedica have?
CalciMedica has 30,736,400 shares outstanding.
What happened to CalciMedica’s price movement after its last earnings report?
CalciMedica reported an EPS of $0.3 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went up 6.599%.
Which hedge fund is a major shareholder of CalciMedica?
Currently, no hedge funds are holding shares in CALC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CalciMedica
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
CALC Stock 12 Month Forecast
Average Price Target
$10.00
▲(1566.67% Upside)
Technical Analysis
Ownership Overview
22.36% Insiders
0.81% Mutual Funds
0.27% Other Institutional Investors
76.27% Public Companies and
Individual Investors